Robert Y. Chen

PGY-4 @UW Psychiatry. Prev MD-PhD @WUSTL. Biomarker and drug discovery for psychiatry, starting with Schizophrenia. Dog Daddy x2 to Taro and Azuki.

[Robert Y. Chen @therealRYC]

🚨 [ONE GENE PROTECTS AGAINST AUTISM]

Autism is 3 to 4 times more common in boys than girls.

For years, we've known females have a "protective effect" against autism mutations, but we didn't know how it worked.

A new @Nature paper just found the molecular buffer: a gene on the X chromosome called ZFX. 🧵

[Robert Y. Chen @therealRYC]

💡 Takeaways

For the first time, we have a concrete molecular mechanism explaining the female protective effect in autism.

Rather than pointing to sex hormones, this paper identifies a transcriptional buffer: ZFX, which is expressed higher in females because it escapes X-inactivation.

By demonstrating that 18 distinct autism genes all collapse the same downstream network, they showed that ZFX acts as a structural reinforcement for that exact network, allowing the female brain to absorb genetic hits that would push a male brain into clinical disease.

The multi-billion-dollar question is whether we can therapeutically upregulate ZFX or its downstream network in males to mimic this resilience and alter the developmental trajectory of autism.

Just think about that for a second: we have a SINGLE gene that could potentially SHIELD against Autism.

Despite Autism being caused by hundreds of different genes that can go wrong, we can make ONE genetic medicine, NOT hundreds.

The implications of convergent biology is profound. One of the reasons I shied away from researching ASD was because I didn't see how a therapy could be reasonably developed when the genetics were so pleitropic.

This paper has changed my mind.

Source: Andersen et al. Nature 2026 — https://t.co/ovK2yuntoT

[Robert Y. Chen @therealRYC]

🚨 [ONE GENE PROTECTS AGAINST AUTISM]

Autism is 3 to 4 times more common in boys than girls.

For years, we've known females have a "protective effect" against autism mutations, but we didn't know how it worked.

A new @Nature paper just found the molecular buffer: a gene on the X chromosome called ZFX. 🧵

[Robert Y. Chen @therealRYC]

🔎 Only modeled in a male cell line

This study proposes a brilliant mechanism for female protection, but the entire experimental platform rests on a single male (XY) iPSC line.

Because they used an isogenic male line to reduce genomic background noise, they could not directly measure whether female (XX) cells actually resist these transcriptomic ripples better than male cells do in a dish.

The buffering effect of ZFX is elegantly deduced from network analysis, gene expression databases, and male autism brain tissue, but the functional "stress test" comparing XX versus XY organoid resilience hasn't been run yet.

Furthermore, they targeted rare, highly penetrant single-gene causes of autism. It remains to be seen if this network also buffers against the common, polygenic risk that drives the vast majority of clinical autism cases.

[Robert Y. Chen @therealRYC]

@jacobkimmel Totally agree. It’s hard not to be a technopptimist in this day and age!

[Robert Y. Chen @therealRYC]

@alokvkulkarni Haha it’s an even stronger proof of mechanism, but I think there can be better designs in next iterations.

[Robert Y. Chen @therealRYC]

Absolutely wild. Thread on this tomorrow the findings are just too bananas.

We are literally living in science fiction but instead it’s just science fact.

[NEJM @NEJM]

In three patients with refractory epilepsy, hippocampal chemogenetic therapy plus low-dose clozapine was associated with a mean seizure-frequency reduction of 92.6%. Adverse events were grade 1 or 2. Full study results: https://t.co/0LM5s02Lbv

[Robert Y. Chen @therealRYC]

@Niah_Stewartson Fair viewpoint, I suppose aspirin was once viewed that way too until it wasn’t

[Robert Y. Chen @therealRYC]

🚨 [BREAKING NEWS]

Novartis just disclosed 9 reports of tumors in children treated with the gene therapy Zolgensma.

Two cases show evidence of vector DNA integration.

That means: the treatment MOST LIKELY caused the tumor.

This is a closely watched safety signal in a CNS drug that revolutionized spinal muscular atrophy. 🧵

[Robert Y. Chen @therealRYC]

@Jn66039675 I asked @zenbrainest (invented DREADDs) this too, and he had a reasonable answer.

Low dose is the key here.

But the idea down the line would be to find something that’s nearly bio-orthogonal to native human biology, in the same way click chemistry is.

[Robert Y. Chen @therealRYC]

🚨 [SCIENCE BREAKTHROUGH]

DREADDs have officially reached human trials.

Chemogenetic neuromodulation aka using viral vectors to install designer receptors in the brain, then activating them with an oral pill, just showed proof-of-concept for refractory epilepsy.

Seizures dropped 92% in 3 patients.

But the real potential is the PLATFORM - I break it down at the end🧵

[Robert Y. Chen @therealRYC]

💡 Takeaways

For decades, DREADDs have been a staple of neuroscience animal labs. This paper successfully translates that chemogenetic control into human patients.

It is a true paradigm shift for neuromodulation. Instead of continuous electrical stimulation or resecting brain tissue, we can now genetically tag a hyperactive network and silence it with a targeted oral drug.

The magnitude of the early response is remarkable, effectively halting refractory seizures in a tiny cohort that had failed multiple standard therapies for decades.

The open question is scalability. Whether this exquisite localized control can be reliably replicated across larger populations and more complex seizure architectures will define its future in clinical neurology.

But here’s where I’m really getting excited.

DREADDS are a general platform for homing a small molecule to a specific target. Let me break it down:

» Small molecules are messy and go everywhere which means off target effects are all but inevitable.

» Genetics are specific: you can have a cell-type specific promoter drive the expression of an on/off switch (an excitatory or inhibitory channel) that only flips when given a small molecule that is highly specific to that receptor.

SO: that means instead of blocking all sodium channels in all neurons, you can block them in just the subset you want.

AND: because we are making single cell RNA atlases of different neuronal cell types with different promoter specificities, we will be able to target a huge diversity of neurons - with SMALL MOLECULES!!

The implications are vast and go far beyond neuropsychiatric diseases.

Imagine treating arrhythmias with DREADDs.

Or cystic fibrosis, which is also primarily a channel disorder?

Lots to leave to the imagination.

Source: Dai et al. N Engl J Med 2026 — https://t.co/waRMCmsqDR

[Robert Y. Chen @therealRYC]

🔎 An open-label surgical trial in three people

Okay. Yes it’s exciting. But this is early days:

The dramatic 92% reduction rests on just three patients, which means we are looking at proof-of-concept safety data, not a powered efficacy measure.

Because this was an open-label surgical intervention, patient placebo response is uncontrolled, though blinded evaluators controlled for rater expectancy. Furthermore, the targeted delivery requires precise, MRI-guided intracranial infusion into a known structural lesion (hippocampal sclerosis).

That limits the immediate generalizability. We do not yet know if this approach will work in non-lesional epilepsy or multifocal disease where the epileptogenic zone is harder to neatly bracket with an infusion trajectory.

[Robert Y. Chen @therealRYC]

@Lorenzo7127 Ic ic all great points, thanks for sharing!